Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2011
Reporting Period: Single event date (June 15, 2011)
The filing reports a regulatory milestone regarding the Company's manufacturing capabilities in Carmiel, Israel.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific corporate event.
Material Changes
Regulatory Approval: Brazil's National Health Surveillance Agency (ANVISA) completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility in Carmiel, Israel. The agency determined the facility is acceptable.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the successful audit but does not provide additional management commentary, financial guidance, or specific risk factors within the text of this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the scope of the ANVISA audit.
- Confirm the implications of the ANVISA approval for the Company's ability to market products in Brazil.
- Review subsequent filings for any financial impact or revenue recognition related to this regulatory milestone.